Plasma proteome and metabolome signatures to better understand, monitor and predict neuroblastoma evolution (B05)

• Subject Area: Hematology, Oncology ; Pediatric and Adolescent Medicine
• Term: since 2023
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 493872418

Project uses ultra-high-throughput proteomics and metabolomics technologies to characterize blood and tumor samples from genetically modified mouse models and patients with high-risk neuroblastoma. By combining proteomic and metabolomic data with existing (epi)genomic data, omics networks in the cell will be illuminated to identify potential biomarkers or signatures in liquid biopsies. The validity of the biomarkers will be assessed in a control cohort to determine their potential to predict disease progression and outcomes). The goal is noninvasive disease surveillance in high-risk neuroblastoma patients.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1588: Decoding and Targeting Mechanisms of Neuroblastoma Evolution
• Applicant Institution: shared FU Berlin and HU Berlin through:; Charité - Universitätsmedizin Berlin
• Project Heads: Dr. Hedwig E. Deubzer, Ph.D.; Professor Dr. Markus Ralser